Vitamin D promotes anticancer effects of low‐concentration cisplatin‐treated non‐small cell lung cancer cells via inhibiting the JAK2/STAT3 and TGF‐β/SMAD4 pathways
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Heba Effat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Lung cancer is one of the most fatal kinds of cancer, with low survival rate because of delayed discovery and traditional therapy failure. This study intends to determine whether cisplatin plus vitamin D could be a more successful combination than standard monotherapy for non‐small‐cell lung cancer (NSCLC) by targeting the transforming growth factor beta (TGF‐β)/mothers against decapentaplegic homolog 4 (SMAD4) and janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathways and their downstream targets. Cytotoxic effects of vitamin D on MCF‐7, MCFR‐10, H1299, A549, and PC3 cell lines were evaluated by sulforhodamine‐B (SRB) assay, indicating that H1299 and A549 were the most effected cell lines; hence, they were selected for more investigation. IC 50 values of cisplatin against H1299 and A549 cells were established. Quantitative polymerase chain reaction (qPCR) was used to assess the expression levels of JAK2, STAT3, TGF‐β, Smad4, matrix metalloproteinase‐2 (MMP‐2), and MMP‐9 in both cell lines treated with vitamin D, cisplatin, or both. Results demonstrated remarkable expression of the aforementioned genes in H1299 and A549 cells, which was sharply decreased once the combination treatment was administered. Additionally, the protein expression of VEGF, MMP9, and angiotensin I, II is considerably inhibited by this combination. According to the obtained data, vitamin D and cisplatin combination therapy can target genes and proteins involved in cell adhesion, migration, and invasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
- Hormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
- Stem Cell Laboratory, Centre of Excellence for Advanced Sciences, National Research Centre, Giza, Egypt.
- Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Förderung
- None
Zitieren
APA
Effat, H., Abohashem, R. S., Sharaky, M., & Mohammed, M. A. (2025). Vitamin D promotes anticancer effects of low‐concentration cisplatin‐treated non‐small cell lung cancer cells via inhibiting the JAK2/STAT3 and TGF‐β/SMAD4 pathways. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400933
Vancouver
Effat H, Abohashem RS, Sharaky M, Mohammed MA. Vitamin D promotes anticancer effects of low‐concentration cisplatin‐treated non‐small cell lung cancer cells via inhibiting the JAK2/STAT3 and TGF‐β/SMAD4 pathways. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400933
BibTeX
@article{Effat2025,
author = {Effat, Heba and Abohashem, Rehab S and Sharaky, Marwa and Mohammed, Mohammed Aly},
title = {Vitamin D promotes anticancer effects of low‐concentration cisplatin‐treated non‐small cell lung cancer cells via inhibiting the JAK2/STAT3 and TGF‐β/SMAD4 pathways},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400933}
}
EUVIMED